2025
Contemporary approaches to treat people with hemophilia: what’s new and what’s not?
Valentino L, Santaella M, Carlson S, Recht M. Contemporary approaches to treat people with hemophilia: what’s new and what’s not? Research And Practice In Thrombosis And Haemostasis 2025, 9: 102696. PMID: 40084158, PMCID: PMC11905833, DOI: 10.1016/j.rpth.2025.102696.Peer-Reviewed Original ResearchComprehensive interdisciplinary careCare of peopleMiddle-income countriesBispecific monoclonal antibodyStandard of careHealth equityNonfactor productsFactor replacementHemophilia AJoint bleedsGenetic therapiesHemophiliaNormal hemostasisMonoclonal antibodiesAnticoagulant mechanismsTargeted inhibitorsUnaffected peersHaemophilia careBleedingNarrative reviewTreatmentTreatment of peopleAverage life expectancyInterdisciplinary careDiagnosis
2019
GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
Barthel F, Johnson K, Varn F, Moskalik A, Tanner G, Kocakavuk E, Anderson K, Abiola O, Consortium G, Huse J, DeGroot J, Stead L, Verhaak R. GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS. Neuro-Oncology 2019, 21: vi103-vi103. PMCID: PMC6847692, DOI: 10.1093/neuonc/noz175.430.Peer-Reviewed Original ResearchAdult patientsOverall survivalDisease recurrencePoor outcomeCurrent therapiesInitial diseaseTreatment optionsTherapy resistanceNeoantigen profilesTherapeutic interventionsPatientsPathway alterationsTumor progressionGlioma Longitudinal Analysis ConsortiumTargeted inhibitorsCancer typesGlioma developmentGliomasDiffuse gliomasGlioma subtypesTime pointsUnderstanding of mechanismsRecurrenceGlioma datasetsHypermutator phenotype
2018
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Cannataro VL, Gaffney SG, Stender C, Zhao ZM, Philips M, Greenstein AE, Townsend JP. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene 2018, 37: 2444-2455. PMID: 29453361, DOI: 10.1038/s41388-017-0105-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmino Acid SubstitutionAnimalsCase-Control StudiesDisease ProgressionDrug Resistance, NeoplasmFemaleGenetic HeterogeneityHigh-Throughput Nucleotide SequencingHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplasmsOncogenesPoint MutationPolymorphism, Single NucleotideProto-Oncogene Proteins p21(ras)Sequence Analysis, DNAYoung AdultConceptsTime of treatmentTargeted therapyLung tumorsDe novo mutationsNew targeted therapiesPatient-derived xenograftsHighest fitness advantageKRAS G12C variantNovo mutationsEvidence of heterogeneityNovel KRAS mutationPreclinical promiseSuch therapyHigh prevalenceKRAS mutationsTreatment resistanceBRAF V600EKRASTherapyTargeted inhibitorsTumorsAssociated oncogeneRAS genesHuman cancersOncogenic mutations
2016
AMPK promotes tolerance to Ras pathway inhibition by activating autophagy
Sanduja S, Feng Y, Mathis RA, Sokol ES, Reinhardt F, Halaban R, Gupta PB. AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. Oncogene 2016, 35: 5295-5303. PMID: 27041569, PMCID: PMC6086350, DOI: 10.1038/onc.2016.70.Peer-Reviewed Original ResearchConceptsCellular energy sensor AMPEnergy sensor AMPPathway inhibitorTargeted inhibitorsRas-Raf pathwayDrug-tolerant cellsPathway inhibitionOncogenic RasProtein kinaseRaf signalingRas pathway inhibitionReduced growthAMPKAutophagyPathway mutationsCancer cellsResistant cellsKey mechanismPathwayInhibitorsCellsToleranceKinaseSignalingInhibition
2010
364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer
Shimizu T, Tolcher A, LoRusso P, Papadopoulos K, Patnaik A, Smith L, Keegan M. 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. European Journal Of Cancer Supplements 2010, 8: 115. DOI: 10.1016/s1359-6349(10)72071-1.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply